Polaryx Therapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Polaryx Therapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
Polaryx Therapeutics, Inc. SEC Filing (Jul 28, 2026)
The story matters when it changes Polaryx Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Polaryx Therapeutics, Inc.: Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol "PLYX"
Investors are testing whether Polaryx Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Polaryx Therapeutics, Inc.: Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq
Investors are testing whether Polaryx Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest PLYX filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Polaryx Therapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →